Demyelinating Disease Assessment

Demyelinating Disease Assessment is a clinical neurophysiological method that quantifies delayed visual evoked potential latencies to objectively detect and evaluate impaired neural conduction due to myelin loss in central nervous system disorders.

216

Publications

12.4K

Citations

1.3K

Authors

463

Institutions

Publications per year

2017–2026

52

Authors

1.3K

  1. CL
    Christine Lebrun‐Frénay

    Inserm, France

    5 publications · 345 citations

    5

    h-index

  2. BB
    Brenda Banwell

    Children's Hospital of Philadelphia, United States

    5 publications · 265 citations

    5

    h-index

  3. DP
    Daniel Pelletier

    University of California, San Francisco, United States

    5 publications · 184 citations

    5

    h-index

  4. MT
    Mar Tintoré

    Vall d'Hebron Hospital Universitari, Spain

    5 publications · 697 citations

    5

    h-index

  5. OH
    Orhun H. Kantarci

    Mayo Clinic, United States

    4 publications · 134 citations

    4

    h-index

1–5 of 1.3K

Venues

  1. Neurology

    20 publications · 2.2K citations

    18

    h-index

  2. Multiple Sclerosis Journal

    MSJ · 19 publications · 766 citations

    17

    h-index

  3. PubMed

    Repository · 19 publications · 1.4K citations

    13

    h-index

  4. Journal of Neurology Neurosurgery & Psychiatry

    11 publications · 674 citations

    11

    h-index

  5. Acta Neurologica Scandinavica

    14 publications · 410 citations

    11

    h-index

1–5